

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gladwin *et al.*

Application No. 10/563,682

Filed: January 6, 2006

Confirmation No. 3411

For: USE OF NITRITE SALTS FOR THE
TREATMENT OF CARDIOVASCULAR
CONDITIONS

FILED VIA EFS

Examiner: Ernst V. Arnold

Art Unit: 1616

Attorney Reference No. 4239-67618-05

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 are 74 English-language documents, nineteen of which are submitted herewith. Applicants respectfully request that all of the documents on the form PTO-1449 be listed on the issued patent as references cited.

This Information Disclosure Statement (IDS) is submitted after the mailing date of an office action on the merits, but before the mailing date of any final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application. Submitted herewith via EFS is payment for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c). Deposit account authority for any additional necessary fees is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. § 1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630